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MyocarditisThe action of transforming-growth-factor (TGF)-β following inﬂammatory responses is characterized by
increased production of extracellular matrix (ECM) components, as well as mesenchymal cell proliferation,
migration, and accumulation. Thus, TGF-β is important for the induction of ﬁbrosis often associated with
chronic phases of inﬂammatory diseases. This common feature of TGF-related pathologies is observed in
many different organs. Therefore, in addition to the description of the common TGF-β-pathway, this review
focuses on TGF-β-related pathogenetic effects in different pathologies/organs, i. e., arthritis, diabetic
nephropathy, colitis/Crohn's disease, radiation-induced ﬁbrosis, and myocarditis (including their similarities
and dissimilarities). However, TGF-β exhibits both exacerbating and ameliorating features, depending on the
phase of disease and the site of action. Due to its central role in severe ﬁbrotic diseases, TGF-β nevertheless
remains an attractive therapeutic target, if targeted locally and during the ﬁbrotic phase of disease.© 2009 Elsevier B.V. All rights reserved.1. Introduction
The ﬁbrotic reaction of the connective tissue following an
inﬂammatory response is mainly characterized by an increased
production of extracellular matrix (ECM) components and mesench-
ymal cell proliferation, migration and accumulation. Despite the
existence of numerous distinct causes of chronic inﬂammatory
diseases in different organs and tissues, these diseases are generally
characterized by: i) severe and intermittent progression with phases
of acute exacerbation and remission; ii) immigration of inﬂammatory
cells (macrophages, granulocytes and T-cells); and iii) increased
expression of pro-inﬂammatory mediators (Fig. 1). These processes
result in the proliferation of local ﬁbroblasts and, by interaction with
epithelial cells, in their differentiation into myoﬁbroblasts and can be
regarded as a misguided wound healing. Finally, the inﬂammatory
process comes to rest, but massive ﬁbrosis prevents a rebuilding of
functionally intact tissue and organs.
Transforming growth factor (TGF)-β is an ubiquitously expressed
cytokine belonging to a large superfamily of activins/bone morpho-Unit, University Hospital Jena,
lle” Eisenberg, Klosterlausnitzer
1228/6.
(R.W. Kinne).
ll rights reserved.genetic proteins [1]. This mediator plays an active role in the processes
discussed above, such as proliferation, wound healing [2], and syn-
thesis of ECM molecules [3]. TGF-β, therefore, strongly contributes to
ﬁbrotic disorders such as diabetic nephropathy, Crohn's disease,
rheumatoid arthritis, radiation-induced ﬁbrosis, and myocarditis.
However, TGF-β is clearly a bi- (or multi-) functional molecule with
strong effects on the immune system [4,5].
2. TGF-β signaling pathway
TGF-β is synthesized as one part of a large molecule, the pro-TGF-β
containing the latency-associated proteins (LAP; Fig. 2). The latter is
cleaved fromTGF-β in the Golgi apparatus, but remains non-covalently
associated with the growth factor. The disulﬁde-bound latent-TGF-β-
binding proteins 1/2 (LTBP 1/2) connect the whole complex to the
ECM (details described in [6]). Release of TGF-β from the pro-TGF-β
complex can be achieved through proteolytic activity by plasmin [7] or
matrix-metalloproteinase (MMP)-2 andMMP-9 [8], through integrins
[9,10] (recently reviewed in [11]), treatment with mild acids [12], or
through the action of thrombospondin (THBS; [13]) by disrupting the
non-covalent interactions between LAP and TGF-β1. Once released,
TGF-β mediates signals through pairs of type I and type II receptors
[14]. The type III receptor (betaglycan) acts – probably in conjunction
with otherheparan sulfate glycans like syndecan [15]– as a co-receptor
Fig. 1. TGF-β1 induces different, but overlapping responses in different organ systems.
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The result of ligand binding is the activation of the type II receptor
(TGFBR2), which then phosphorylates the type I receptor (TGFBR1).
The active receptor complex then phosphorylates the so-called R
(receptor)-Smad2 or Smad3 that propagates the signal [17]. The
phosphorylation of Smad2/3 decreases the afﬁnity for the Smad-
anchor for receptor activation (SARA), which in non-stimulated cells
mediates the retention of Smad2/3 in the cytoplasm by interaction,
and increases the afﬁnity of Smad2/3 for Smad4 (a so-called co-Smad).
This complex is now able to enter the nucleus, to bind transcriptional
co-activators like p300 and Creb-binding-protein (CBP) or repressors
like SkiL or TGIF [18], and to regulate the transcriptional activity of
various genes.
Mitogen-activated protein kinases (MAPKs) and protein kinase C
can also interfere with either the nuclear translocation or binding of
Smad3/4 complexes to DNA and regulate TGF-β1 signalling [19,20].
Moreover, the serine–threonine protein kinase B can directly interact
with Smad3, thereby preventing its phosphorylation and nuclear
translocation [21]. Other pathways can be directly activated by TGF-β1.
These include components of the MAPK pathway, such as ras, raf, ERK,
p38 and JNK, the phosphatidylinositol-3 kinase cascade, as well as the
regulators of cadherin junctions, RhoA and Rac ([19,22,23]; Fig. 2).
Recently, an involvement of the focal adhesion kinase (FAK) has been
established in myoﬁbroblast differentiation and in remodeling of the
connective tissue following stimulation with TGF [24,25]. In line with
these results, TGF-induced FAK-signaling is required for the activation
of TAK [26] or MEKK1 and, subsequently, of JNK [27], all factors shown
to be essential for the transcription of pro-ﬁbrotic genes.
Notably, these signal transduction pathways have their own
intracellular regulators. An inhibitory Smad (Smad7) blocks TGF-β1
signaling by physical interaction with the activated TGFBR1 receptor
and prevents the docking and phosphorylation of Smad2/3 [28,29].
This complex TGF-β signaling pathway (Fig. 2) contains numerous
ligands, receptors, and signaling molecules which, as potential targets
of dysregulation via increased or decreased expression, activationor interaction, may be partially involved in ﬁbrotic reactions in the
diseases discussed below.
3. TGF-β-related molecules in rheumatoid arthritis
The importance of TGF-β1 in rheumatoid arthritis (RA) ranges
from an association with certain vascularization patterns in the
synovial membrane (SM) [30], and an association of TGF-β poly-
morphisms with the radiological signs of joint destruction [31] to an
induction of pro-inﬂammatory cytokines, MMP [32], aggrecanase [33]
and urokinase-type plasminogen activator [34]. In addition, TGF-β
plays an important role for the function of regulatory T-cells [5] in the
suppression of autoimmunity. Indeed, increased levels of TGF-β1 have
been found in the synovial membrane of patients with RA by northern
blot [35], immunohistochemistry [36,37], western blot [38] and in
synovial effusions [39]. Also TGFBR2 was detected at higher levels
than in normal synovial tissue [35].
Using “pathway-directed” software following genome-wide
comparison between synovial ﬁbroblasts (SFB) from patients with
RA and osteoarthritis (OA) with Affymetrix arrays, gene expression
of TGF-β1, TGF-β3, LTBP1/2, THBS1, TGFBR1, SARA, CBP, SkiL –
belonging to the TGF-β-pathway (Fig. 2) – was elevated in RA [40].
After validating array data at the mRNA and protein levels using
quantitative PCR and western blot/immunohistochemistry, we
conﬁrmed an upregulated TGF-β pathway in RA-SFB. The presence
of TGF-β1, in conjunction with increased amounts of TGF-β-
releasing THBS1 and a higher expression of TGFBR1, may thus
lead to an ampliﬁed response of RA-SFB to TGF-β. This RA-speciﬁc
response has been conﬁrmed by increased expression of MMP-11
following TGF-β stimulation, implying a pathogenetic relevance of
the TGF-β-pathway for MMP-induced degradation or remodeling
processes in RA [40].
The importance of TGF-β for the pathogenesis of arthritis is empha-
sized by a number of animal models. The abundant expression of TGF-
β1, 2, and 3 aswell as the TGFBR1 and -2 in rat synoviumwas increased
Fig. 2. Molecules of the TGF-β-pathway ranging from the release of TGF-β, binding of receptors, signaling through Smads, FAK and MAPK to its entry into the nucleus and the
regulation of the transcriptional activity (adapted from [40]).
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intra-articular injection of TGF-β1 or TGF-β2 induced synovial
erythema, swelling, and cellular inﬁltration resulting in synovial in-
ﬂammation and hyperplasia [42]. Conversely, neutralization of TGF-β
inhibited acute and chronic arthritis induced by streptococcal cell walls
(SCW) [43]. In line with these observations, an adenovirus-mediated
overexpression of TGF-β1 in rabbit knees led to an increased glyco-
saminoglycan release, nitric oxide production and, most notably, to
ﬁbrosis andmuscle edema [44]. The prevention of CIA by administration
of a TGFBR1 inhibitor (HTS466284), which concomitantly reduced the
expression of vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF)-AA, TNF-α, and cellular proliferation
[45], further underlines the pathogenetic role of TGF-β in arthritis.
In contrast to the above-mentioned studies, numerous observa-
tions show beneﬁcial effects of TGF-β in arthritis. If administered
systemically, TGF-β1 suppressed SCW-induced arthritis, as measured
by cellular inﬁltration and joint erosion [46]. In addition, investigation
of the cytokine expression during CIA demonstrated a strong up-
regulation of TGF-β1/2 in the remission state of disease, possibly
reﬂecting the anti-inﬂammatory regulation of T-cells by TGF-β in
arthritis. If TGF-β signaling was inhibited by expression of dominant-
negative TGFBR2 in T-cells [47] the susceptibility and the clinical
severity of CIA was strongly increased. Likewise, if TGF-β1 was
retrovirally overexpressed in arthritogenic splenocytes, CIA could not
be transferred to SCID mice and established disease was ameliorated
[48]. Therefore, it may be important to inhibit TGF-β only at the site
of inﬂammation without targeting regulatory lymphocytes at extra-
articular sites.4. TGF-β-related molecules in diabetic nephropathy
TGF-β and its signal transduction play a major role in diabetic
nephropathy and have therefore been thoroughly studied [49–53].
Among the features of the diabetic milieu, hyperglycemia, increased
non-enzymatic glycation of proteins, de novo synthesis of diacylgly-
cerol and subsequent activation of protein kinase C, increased
intracellular glucosamine production, and enhanced renal production
of vasoactive agents (angiotensin II, endothelins, thromboxane) have
all been shown to increase the expression of TGF-β in cultured renal
cells and animal models of diabetic nephropathy [50,52,54].
The TGF-β level is elevated in the kidneys of insulin-dependent
diabetic animals during both early and late stages of disease [53,54].
Treatment of the streptozotocin (STZ)-diabetic rat with sufﬁcient
insulin to reduce hyperglycemia suppressed the enhanced expression
of TGF-β and matrix components in the glomeruli. In the STZ-diabetic
rat and mouse, increased TGF-β1 expression in the renal cortex and
glomeruli as well as up-regulation of the TGFBR2 mRNA and protein
was noted early after the onset of diabetes [53]. The db/db mouse, a
model of type 2 diabetes, characterized by hyperglycemia, obesity, and
insulin resistance, develops increased amounts of TGF-β1 localized in
the glomerular compartments [55]. In contrast, the mRNA and protein
levels of the TGFBR2 are signiﬁcantly up-regulated in both the
glomerular and the tubulointerstitial compartments [55].
The development of diabetic renal hypertrophy and glomerulo-
sclerosis is likely caused by heightened activity of the TGF-β system
[56–63]. Short-term treatment of the STZ-diabetic mouse with a
neutralizing monoclonal antibody against all three isoforms of TGF-β
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weight by 50%, and signiﬁcantly attenuated the increase in TGF-β1, α1
(IV) collagen, and ﬁbronectin mRNAs without affecting glycemic
control [56]. The results of this study suggested a cause-and-effect
relationship between the renal TGF-β system and the development of
early structural changes in diabetic nephropathy. Systemic anti-TGF-β
therapy for 8 weeks prevented the mesangial matrix expansion of
diabetic glomerulosclerosis and, most importantly, preserved kidney
function, showing for the ﬁrst time that neutralization of TGF-β acti-
vity prevents the progression of renal failure in diabetes [57].
However, the anti-TGF-β antibody did not reduce albuminuria,
which itself may promote the progression of renal insufﬁciency [57].
The paradox of preserved renal function in view of persistent
albuminuria may be explained by postulating that the deleterious
effects of proteinuria are themselves mediated by the TGF-β system
[63–65].
In mouse mesangial and tubular cells, high glucose stimulates the
transcription of ﬁbronectin and, in addition, potentiates the transcrip-
tional activation of ﬁbronectin by TGF-β1 [58,59]. This particular effect
of TGF-β1 appears to be mediated by Smad3, because over-expression
of Smad3 alone was able to induce ﬁbronectin promoter activity [66].
In conjunctionwith exogenous TGF-β1, Smad3 over-expression syner-
gistically increased ﬁbronectin expression, as if the extra Smad3 had
increased the efﬁciency of TGF-β signaling [66]. Finally, transfection of
a Smad3-dominant-negative construct inhibited TGF-β1 stimulated
ﬁbronectin promoter activity [67,68]. However, part of the TGF-β1-
induced ﬁbronectin expression may be mediated in parallel by the
p38MAPK pathway [68,69]. Finally, there is evidence that Smad3 is a
central mediator in the TGF-β1-induced increase of mRNA expression
for α1(I) collagen [68,70]. TGF-β-induced MAPK activation also leads
to N-terminal phosphorylation of p53 that enables its interactionwith
TGF-β-activated Smads [64], an indication for cross-talk between the
various TGF-β signaling pathways.
TGF-β1 may have additional effects besides the stimulation of
extracellular matrix production. In podocytes, TGF-β1 induces
apoptosis through Smad7 by inhibiting nuclear translocation of the
cell survival factor NF-κB [70]. TGF-β1-mediated activation of Smad7
is speciﬁc for podocytes and is not found inmesangial cells in a limited
series of biopsies from patients with diabetic nephropathy [64]. Since
podocytes are terminally differentiated cells unable to undergo cell
division due to the up-regulation of the cell cycle inhibitory proteins
p57 and p27Kip1, apoptotic loss of cells was not replaced.
Studies performed in diabetic patients with various degrees of
nephropathy also underline the importance of the renal TGF-β system
in disease development [71–73]. All three isoformsof TGF-β are elevated
in both the glomerular and the tubulointerstitial compartments of
patients with established diabetic nephropathy [71,72]. Furthermore,
glomerular TGF-β1 mRNA is markedly increased in biopsy specimens
from patients with proven diabetic kidney disease. These investigations
suggest that increased renal TGF-β levels closely correlate with the
degree of mesangial matrix expansion, interstitial ﬁbrosis, and renal
insufﬁciency.
Another study, designed to assess renal production of TGF-β [73]
measured aortic, renal vein, and urinary levels of TGF-β in 14 type 2
diabetic and 11 non-diabetic control patients undergoing elective
coronary artery catheterization [73]. Both groups were roughly
matched with regard to the range of renal function and the presence
of hypertension and proteinuria. Renal blood ﬂow was measured to
calculate the net mass balance across the kidney. The gradient of
TGF-β1 concentration across the renal vascular bed was negative in
the non-diabetic patients indicating net renal extraction of TGF-β1,
whereas the gradient was positive in the diabetic patients indicating
net renal production of TGF-β1. When the renal TGF-β1 mass balance
was calculated, a similar pattern was observed with the non-diabetic
kidney removing approximately 3500 ng/min of TGF-β1 from the
circulation, and the diabetic kidney adding approximately 1000 ng/minof TGF-β1 [73]. In addition, the level of bioassayable TGF-βwas increased
four-fold in the urine of diabetic versus non-diabetic patients. This was
not simply a function of enhanced glomerular permeability to protein
since diabetic patients both with and without microalbuminuria
displayed similarly high rates of urinary TGF-β excretion [73]. These
results demonstrated that the kidneys of diabetic patients overproduce
TGF-β1 protein; further details, e. g., the exact contribution of the
different renal cell types, need to be investigated.
An interesting post-hoc study assessed whether treatment with
the angiotensin converting enzyme inhibitor captopril would lower
serum TGF-β1 levels in a small subset of patients with diabetic
nephropathy who had been enrolled in the Collaborative Study Group
[74,75]. After 6 months, the serum TGF-β1 level decreased signiﬁ-
cantly by 21% in the captopril-treated group, whereas it increased
slightly by 11% in the placebo-treated group [75]. Interestingly, the
captopril-treated patients with decreased serum TGF-β1 levels
tended to have better preserved renal function over the ensuing
two-year period [75]. This association was even more pronounced in
the subset of patients with an initial glomerular ﬁltration rate of less
than 75 ml/min. These results suggest that TGF-β1 plays a pivotal
role in the progression of diabetic nephropathy and that angiotensin
converting enzyme inhibitor therapy may protect the kidney by
lowering TGF-β1 production.
5. TGF-β-related molecules in intestinal inﬂammation — a
double-sided sword
TGF-β is constitutively expressed by epithelial cells, ﬁbroblasts,
and mononuclear cells in the gastrointestinal tract [76]. Its critical role
in intestinal homeostasis as a negative master regulator of inﬂamma-
tion is well-established [77,78] and indisputable. However, translation
of elegant mouse experiments into therapeutic interventions in
humans requires a clearer understanding of TGF-β activity in the
human gut. Mice with global TGF-β defects, such as TGF-β-null mice
or transgenic mice expressing a dominant negative TGFBR2 chain, are
unresponsive to TGF-β1 signaling. The former die soon after birth due
to systemic inﬂammation, and the latter develop severe colonic and
pulmonary inﬂammation [79,80]. These manifestations of global
TGF-β1 defects are mirrored in mouse models of colitis in that the
secretion of TGF-β1 is consistently associated with either the
protection from colitis or a greatly diminished severity of colitis. This
is seen both in the TH1 model of colitis induced by the haptenating
reagent trinitrobenzene sulfonic acid (TNBS), which mimics Crohn's
disease (CD), or the TH2 model of colitis induced by the haptenating
agent oxazolone, which mimics ulcerative colitis (UC) [81,82]. In
addition, it is seen in the colitis of SCID or RAG2-deﬁcient mice
receiving CD45RBhigh (naive) T cells in which the protective effect of
the cotransfer of CD45RBlow T (memory) cells is abolished by
concomitant administration of a neutralizing TGF-β1 antibody [83].
These and other studies quite conclusively establish that TGF-β1 plays
an essential, regulatory role in the control of colitis. On the other hand,
in mice TGF-β1 in combination with IL-6 induces a strong pro-
inﬂammatory TH17 cell differentiation [84–86]. Notably, in humans
TGF-β1 does not have a direct effect on the development of human
TH17 cells, but it can indirectly favour the development of these cells by
suppressing the expression of T-bet and selectively inhibiting the
expansion of IFN-γ-producing T cells [87–89].
The important role of Smad3 as an essential mediator of TGF-β1-
induced anti-inﬂammatory and suppressive activities at the mucosal
level emerges from studies in mice with targeted deletion of the
Smad3 gene. The animals are viable, but die from defects in mucosal
immunity at 1–6 months of age. Mutant mice show diminished cell
responsiveness to TGF-β1, massive inﬁltration of T cells, and multiple
pyogenic abscesses in the stomach and intestine [87,90]. When Smad
signaling was studied in normal human gut mucosa, whole biopsies or
isolated lamina propria mononuclear cells, a basal level of phospho-
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lated by the addition of exogenous TGF-β1 [91].
TGF-β has been also implicated as a key inducer of epithelial–
mesenchymal transition (EMT) [92–97]. Amongst others, EMT is an
essential component of tissue remodeling and wound repair
(reviewed in [98,99]) and ﬁbrosis (reviewed in [100]). During this
transition, the epithelial phenotype, characterized by strong cell–cell
junctions and polarity, is replaced by a mesenchymal phenotype, with
reduced cell–cell interactions, a ﬁbroblastic morphology and
increased motility. TGF-β stimulates the proliferation of many cell
types, particularly those of mesenchymal origin, and it is also a potent
inhibitor of epithelial cell proliferation. EMT in response to TGF-β1
and in ﬁbrosis is mediated predominantly via Smad-dependent
(mainly Smad3) pathways [101,102]. A loss of Smad3 in mice blocked
both morphological changes of lens epithelium to a mesenchymal
phenotype and expression of EMT markers in response to injury in
vivo or to exposure to exogenous TGF-β in organ culture [101].
CD is a chronic, progressive disease of the gastrointestinal tract
with an unknown etiology. It is characterized by transmural inﬂam-
mation of all layers of the bowel wall. The formation of stenoses and
strictures is common in this disease, which causes abdominal pain,
anorexia, and weight loss. Approximately 50% of CD patients undergo
surgery for this type of complication during a 10-year course; how-
ever, the recurrence rate after surgery is high. In contrast, UC rarely
causes intestinal stenosis. Cytokines released from inﬂammatory cells
have long been implicated in the pathogenesis of intestinal ﬁbrosis.
TGF-β/Smad signaling plays an important role in CD [103–105]. The
transmural inﬁltrate of CD is responsible for initiating and maintain-
ing a series of connective tissue changes not only involving the
mucosa, but also the submucosa and muscularis mucosae and muscu-
laris propria, where a marked increase of collagen type I, III, and V
mRNA is observed [106,107]. TGF-β has been identiﬁed as one of the
central growth factors/cytokines that speciﬁcally induces a ﬁbrotic
response after inﬂammatory injury in the intestinal tract. In CD, there
is a marked overexpression of TGF-β1 and TGFBRs in the colonic
mucosa [76,108]. Fibrosis in CD can therefore be interpreted as an
aberrant healing response to mucosal injury [109]. In addition, TGF-β
appears to be involved in intestinal ﬁbrosis in other enteropathies,
such as radiation enteritis, collageneous colitis, and intestinal graft-
versus host disease [110–112]. Both TGF-β and its receptors are
overexpressed in the intestine of patients with CD [113]. Intestinal
ﬁbroblast expression of TGF-β isoforms varies according to the nature
of tissue. Fibroblasts from normal and inﬂamed mucosa both express
the TGF-β1 and TGF-β3 isoforms, while those from ﬁbrotic tissue
show reduced expression of TGF-β3, but enhanced expression of TGF-
β2 and TGF-β1 [114]. This is remarkable, since the TGF-β1 and TGF-β2
isoforms have been speciﬁcally implicated in pathogenic ﬁbrosis,
while TGF-β3 appears to have antiﬁbrotic properties [115]. Monte-
leone et al. have provided insight into the failure of TGF-β down-
regulation in CD. Despite the abundant expression of TGF-β in the
mucosa of patients with CD, phospho-Smad3 is diminished in the
mucosa compared to control mucosal samples, as is the complex of
Smad3 with Smad4. This may be due to the induction and over-
expression of Smad7 in the mucosa of patients with CD and UCs [116].
However, upregulation of Smad7 is not speciﬁc for inﬂammatory
bowel disease (IBD), but also occurs in Helicobacter pylori-induced
gastritis [117]. In addition, mucosal T cells in both whole tissue and
isolated cells show defective TGF-β1 signaling as measured by
reduced immuno-reactivity against phospho-Smad3 [117]. Speciﬁc
anti-sense oligonucleotides for Smad7 reduce expression of Smad7 in
cells isolated from IBD patients which then become responsive to
exogenous TGF-β1. TGF-β1 cannot inhibit pro-inﬂammatory cytokine
production in isolated lamina propria mononuclear cells from CD
patients, but inhibition of Smad7 with anti-sense oligonucleotides
restores TGF-β1 signaling and allows TGF-β1 to inhibit cytokine
production. In inﬂamed mucosal tissue explants from CD patients,inhibition of Smad7 also restores phospho-Smad3 and decreases pro-
inﬂammatory cytokine production, an effect which is partially blocked
by anti-TGF-β1. The extension of these studies examined the
interactions between Smad signaling and NF-κB activation in inﬂamed
gut: while TGF-β1 is a potent inhibitor of TNF-α-induced NF-κB
activation in normal gut, it has no activity in inﬂamed gut. This can be
attributed to over-expression of Smad7, since treatment of cells from
inﬂamed gut with anti-sense to Smad7 allows TGF-β1 to rapidly
down-regulate NF-κB activation [117].
If it becomes possible to speciﬁcally inhibit Smad7, endogenous
TGF-β1 in the inﬂamed gut may negatively regulate pro-inﬂammatory
cytokine production and NF-κB activation, the major components of
the immune overactivity which drives tissue injury in IBD. At the same
time, however, it is important to discover the factors which control
Smad7 expression in the inﬂamed gut. Furthermore, cell-speciﬁc
expression of Smad7 will be important because TGF-β1 has different
effects on different cell types. Thus, while blocking Smad7 will allow
TGF-β1 to reduce pro-inﬂammatory cytokine production by Tcells and
macrophages, it may allow TGF-β1 to increase collagen production in
myoﬁbroblasts, resulting in ﬁbrosis. However, at the moment the
relative importance of the known inducers of Smad7 in the gut, such
as IFN-γ or TNF-α, or even whether TGF-β1 itself induces Smad7 in a
negative regulatory loop, is still unclear.
6. TGF-β-related molecules in radiation-induced ﬁbrosis
TGF-β1 levels are increased in irradiated mouse skin [118,119] and
decrease slowly after irradiation in both pig and human skin [120,121].
Following microvascular hard or soft tissue transfer, TGF-β1 is again
upregulated in a biphasic manner. The ﬁrst expression peak on day 3
post operation is due to enhanced activation of latent TGF-β1 by
extracellular enzymes while the second between day 14 and 28 after
surgery is a result of de novo synthesis [122]. Its most important
signaling receptor TGFBR2 is upregulated in irradiated graft beds as
well [123]. Signaling leads to increased nucleoplasmatic shuttling of
active Smad2/3 and induction of TGF-β1 target genes in ﬁbrotic
healing, which is mainly due to decrease in cytoplasmatic levels of the
inhibitory Smad7 [124].
As a consequence, the extracellular matrix is qualitatively and
quantitatively altered [125]. Prolyl-hydroxyprolinase-β overexpres-
sion [126] promotes synthesis of collagen I, III and IV [124], while
repression of degrading enzymes, such as MMP-1 and induction of
tissue inhibitors [127] suppresses the degrading pathways. Moreover,
integrin surface receptors, such as α2β1 integrin are up-regulated as
well andmodulate transmission of tensile forces [128]. In the presence
of such forces ﬁbroblasts differentiate into myoﬁbroblasts resulting in
constrictive ﬁbrosis [129].
Irradiation-induced ﬁbrosis and damage to the microvasculature
lead to wound healing disorders following surgery in previously
irradiated areas. Such disorders are dependent, in part, on the
radiation dosage and the timing of surgery after irradiation [130,131]
and reduce the success rate of free ﬂaps to 90% compared with 94% in
non-irradiated graft beds [132].
Taking the central role of TGF-β1 in radiation-impaired wound
healing into account, the question of whether TGF-β1-levels differ in
the healthy tissue between different patients is of utmost importance.
It has been demonstrated that patients with an increased TGF-β1
plasma level exhibit an increased risk of developing skin ﬁbrosis
following irradiation [133]. To ﬁnd a particular predictor which
sufﬁciently corresponds with the frequency to develop wound healing
complications following surgery in previously irradiated graft beds
would give a large clinical impact on planning individual treatment
protocols. The availability of reliablemarkersmay eventually allow the
prediction of outcome prior to commencement of treatment, and thus
allow modiﬁcation of combined protocols to minimize late adverse
effects without compromising tumor control.
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Heart ﬁbrosis is a hallmark feature of the chronic stage of viral
myocarditis [134,135]. Human pathogenic coxsackievirus B3 (CVB3) is
considered themost frequent viral cause of chronicmyocarditis inmen
[136]. Clinical manifestations of acute myocarditis vary from ﬂu-like
symptoms to the fulminant fatal forms. Frequently, acute myocarditis,
with distinct onset, follows a monophasic clinical course, and the
majority of patients recover spontaneously after several days of
congestive heart failure. Some patients progress into subacute or
chronic forms, which ultimately lead to death. The molecular mecha-
nisms underlying ﬁbrosis development in chronic myocarditis are
currently not well understood.
Like humans, mice develop a marked age-related susceptibility to
CVB infections [137]. The myocardial lesions in mice closely resemble
those seen in human disease [138]; therefore, experimental murine
models of coxsackievirus-induced myocarditis have been developed
to investigate the pathogenesis of this disease. Although chronic
inﬂammation is characteristic for the human disease as well as for
respective mouse models of ﬁbrosis is more prevalent in the latter.
Excessive ﬁbrosis, as it occurs under conditions of chronic myocar-
ditis, can be classiﬁed as either replacement ﬁbrosis, when functional
tissue is replaced by connective tissue, or as reactive ﬁbrosis, which is
part of an adaptive process [139]. In addition to collagen, tenascin C, and
ﬁbronectin, splice variants of these molecules are often part of the
ﬁbrotic tissue [140,141]. Various cytokines and growth factors are
believed to contribute to the induction ofﬁbrosis, including TGF-β [142],
IL-1, [143], TNF-α [144,145], and PDGFs [146,147]. For example,
persistent expression of cytokines in the chronic stage of CVB3-induced
myocarditis has been described for various mousemodels [148–150], as
well as for human dilatative cardiomyopathy [151]. New observations
suggest that sustained pro-inﬂammatory signaling is associated with a
pro-ﬁbrotic phenotype based on TGF-β-mediated signaling [152].
For ﬁbrogenesis in the heart, members of the PDGF family are
apparently important mediators. Transgenic overexpression of PDGF-
C and PDGF-D, two more recently discovered PDGF isoforms [153], in
the heart leads to massive cardiac ﬁbrosis [146,147]. Therefore, the
importance of PDGF for the pathology of chronic myocarditis was
investigated in mice with CVB3-induced myocarditis. Interestingly, all
analysed isoforms of PDGF, i.e., PDGF-A, -B, and -Cwere upregulated in
close correlation with the inﬂammatory process. High levels of the
growth factors persisted only in MHC class II knockout mice, which
develop a chronic myocarditis upon CVB3 infection, whereas immu-
nocompetent C57BL/6 wild-type mice exhibited only an acute,
completely reversible myocarditis [154,155].
Furthermore, it has been shown that the PDGF-receptor (PDGFR)
blocker Imatinib inhibits activation of resident PDGFR, and attenuates
ﬁbrosis in this mouse model signiﬁcantly [156]. These data strongly
suggest that elevation of PDGF levels and subsequent activation of
PDGFR causally contribute to the type of cardiac ﬁbrosis which occurs
in this model. Efﬁcacy of Imatinib for attenuation of ﬁbrosis has
recently been reported also for other organs, i.e., liver, joints, kidney,Table 1
Expression of TGF-β related proteins in human disease compared to controls (normal or in
Organ Irradiated skin Heart Synovial membrane
Disease Wound healing Fibrotic heart diseases⁎ RA
Molecule
THBS1 n.d. ↑ [178,179] ↑ [40,180]
Latent-TGF-β ↑ [122] n.d. ↔ [183], ↑ [39]
TGF-β1 ↑ [122] ↑ [184,185] ↔ [35,36,40,183], ↑ [3
TGF-β2 ↑ [122] ↔ [185] ↔ [35,183]
TGF-β3 ↓ [187] ↑ [185] ↔ [35,183]
TGFBR1 n.d. ↓ [184] ↑ [40]
TGFBR2 ↑ [123] ↔ [184] ↑ [35,183]
↑ increased, ↓ decreased,↔ no change, n.d. not determined; ⁎mostly following myocardialand lung [157–160]. It can therefore be assumed that Imatinib-
sensitive tyrosine kinases play a more general role in ﬁbrogenesis. In
addition to the PDGFR [157,160], the Abelson tyrosine kinase (c-Abl), a
mediator of TGF-β-signaling [161], has also been proposed as a
relevant target for Imatinib in the inhibition of ﬁbrogenesis [159,162].
While our data [156], and data of others [146,147] strongly suggest a
causal involvement of the PDGFR in ﬁbrogenesis, they do not exclude
that c-Abl activity is also involved in ﬁbrogenetic signalling. It could
function downstream of TGFBRs, but also partially mediate signalling
of the activated PDGFR [163]. It is known that TGF-β can drive cardiac
ﬁbrosis when overexpressed in the mouse heart [164] and the use of
geneticmousemodels to understand the role of TGF-β signalling in the
heart is reviewed in [165]. But the relative contribution of the different
TGF-β-mediated signalling mechanisms to ﬁbrosis in our model of
CVB3-induced chronic myocarditis remains to be fully elucidated.
8. Differences and similarities of TGF-β in different organs
As presented in Table 1, numerous molecules have similar
expression patterns in the diseases mentioned in this review. Due to
limited information from the human system, some datawere replaced
by results derived from the respective animal model (ﬁbrosis
following irradiation).
TGF-β1 is elevated in most pathologies in its active or latent form
and shows similarities with the isoform TGF-β2 in most cases. In
contrast, the expression of TGF-β3 varies fromdown-regulation during
wound healing and CD, abundance without regulation in rheumatoid
arthritis and UC, to up-regulation during diabetic nephropathy. If
determined, the expression of TGFBR2 is often enhanced during
disease. The widespread appearance of the term “n.d.” points out the
urgent need for further investigation of the expression and the effects
of TGF-β-relatedmolecules in humandiseases associatedwith ﬁbrosis,
particularly at the stage of signaling and transcriptional regulation.
9. Therapeutic strategies
As either increased or decreased activity of the TGF-β pathway has
been implicated in the pathogenesis of different human diseases,
methods for increasing or decreasing signaling through these path-
ways are required [166]. There are some tools for enhancing TGF-β
signals, e. g., direct administration of the ligand, usage of agonists, and
increased expression of receptors or decreased expression of signaling
antagonists.
On the other hand, there are different ways to inhibit TGF-β
signaling, e. g., administration of neutralizing antibodies, application
of soluble receptors, usage of antisense nucleotides, and chemically
synthesized inhibitors of the receptor serine/threonine kinases.
Regarding TGF-β inhibition, some clinical trials have been
performedwith neutralizing antibodies, especially in ﬁbrotic diseases,
including a TGF-β2 neutralizing antibody (lerdelimumab) which
effectively decreased the amount of scarring after glaucoma surgery
[167]. A TGF-β1 neutralizing antibody (CAT-192, metelimumab) hasﬂammatory).
Gut Kidney
CD inﬂamed CD ﬁbrotic UC Diabetic nephropathy
↓ [181] n.d. ↔ [181] ↑ [182]
n.d. n.d. n.d. ↑ [182]
7,38] ↑ [76,108,114] ↑ [108,114] ↑ [76,108,114] ↔ [186], ↑ [53,72]
↑ [114] ↑ [114] ↔ [114] ↑ [72]
↓[114] ↓ [114] ↔ [114] ↔ [186], ↑ [72]
↔ [113] n.d. n.d. n.d.
↑ [113] n.d. n.d. n.d.
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which causes scarring in skin and internal organs, however, without
any evidence of efﬁcacy and with more adverse events and serious
adverse events in verum than in placebo patients [168]. This raises the
question of whether broader or even complete blockade of the TGF-β
axis will be safe or rather associated with substantial toxicity [168].
Despite these concerns, a pan-TGF-β (GC-1008) neutralizing antibody
has recently being administered to patients with idiopathic pulmonary
ﬁbrosis in a phase I clinical trial for safety evaluation [169] and is being
administered to patients with focal segmental glomerulosclerosis [170],
renal cell carcinoma, and malignant melanoma [171]; however, safety
and efﬁcacy data from these studies are not yet available.
Similar to neutralizing antibodies, soluble TGF-β superfamily
receptors abrogate signaling at the ligand level by binding the ligand
and preventing it from binding to its cell surface receptors. Due to the
lack of studies in humans, only data from animal models are available.
For example, soluble TGFBR3 has demonstrated efﬁcacy against renal
damage progression associated with diabetes in mice [172]. Similarly,
soluble TGFBR2 has anti-cancer effects in mice, as it suppresses the
growth andmetastasis of pancreatic cancer cells [173] and also inhibits
breast cancer cell growth, migration, invasion, and metastasis [174].
Using anti-sense oligonucleotides to reduce the expression of TGF-
β superfamily members is a relatively new therapeutic tool that has
been already successfully applied in clinical trials for cancer treatment
[175,176]. Also, small molecule inhibitors have been introduced to
block TGF-β signaling. The TGFBR1-inhibitor Ly573636, which blocks
intrinsic receptor-kinase activity, is currently being assessed in
patients with certain cancers (see [176]), whereas other TGFBR1-
inhibitors have shown to be efﬁcient in mouse tumor models [177].
10. Conclusions
Due to the central role of TGF-β in severe ﬁbrotic diseases (with
similarities and dissimilarities among organs/diseases) it is an
attractive therapeutic target, as already shown in several clinical
trials (see above).
The strongly bifunctional role of TGF-β, however (pro-ﬁbrotic, but
anti-inﬂammatory), requires great care for the application of TGF-β-
directed treatments. Future strategies will therefore have to focus on
developing suitable tools to address this bifunctionality such as: 1)
locally or regionally restricted administration of agonists or antago-
nists (in particular, broad TGF-β blockade by agents such as TGF-β
antibodies, TGF-β receptors (soluble/anti-sense), latency-associated
peptide or Smad7; 2) phase-dependent application in those periods of
disease dominated by the critical pathogenetic features of TGF-β; and
3) development of local or systemic biomarkers indicative of a future
favorable response. The systemic applicability of broad TGF-β
blockade will have to await the safety date from ongoing trials.
Acknowledgements
The authors thank Ulrike Körner, Simone Schönfelder, Soo-Yeon Lee,
Christin Thiele and Nora Moll for excellent technical assistance.
Monique Nürnberger and E. Palombo-Kinne are gratefully acknowl-
edged for critical reading and/or editing of themanuscript. Thework of
R. W. Kinne was supported by the Deutsche Forschungsgemeinschaft
(Ki439/6, Ki439/7), the Interdisciplinary Center of Clinical Research
Jena(FKZ010405), and the JenaCenterof Bioinformatics (FKZ0313652B).
G. Wolf received grants from the Deutsche Forschungsgemeinschaft
(Wo 460/14-1,14-2) and the Interdisciplinary Center of Clinical Research
Jena.
References
[1] Y. Shi, J. Massague, Mechanisms of TGF-beta signaling from cell membrane to the
nucleus, Cell 113 (2003) 685–700.[2] B.J. Faler, R.A. Macsata, D. Plummer, L. Mishra, A.N. Sidawy, Transforming growth
factor-beta and wound healing, Perspect. Vasc. Surg. Endovasc. Ther. 18 (2006)
55–62.
[3] B.A. Hocevar, P.H. Howe, Analysis of TGF-beta-mediated synthesis of extracellular
matrix components, Methods Mol. Biol. 142 (2000) 55–65.
[4] M.O. Li, R.A. Flavell, TGF-beta: a master of all T cell trades, Cell 134 (2008)
392–404.
[5] S.M. Wahl, W. Chen, Transforming growth factor-beta-induced regulatory T cells
referee inﬂammatory and autoimmune diseases, Arthritis Res. Ther. 7 (2005)
62–68.
[6] J.P. Annes, J.S. Munger, D.B. Rifkin, Making sense of latent TGFbeta activation,
J. Cell. Sci. 116 (2003) 217–224.
[7] Y. Sato, D.B. Rifkin, Inhibition of endothelial cell movement by pericytes and
smoothmuscle cells: activation of a latent transforming growth factor-beta 1-like
molecule by plasmin during co-culture, J. Cell Biol. 109 (1989) 309–315.
[8] Q. Yu, I. Stamenkovic, Cell surface-localized matrix metalloproteinase-9
proteolytically activates TGF-beta and promotes tumor invasion and angiogen-
esis, Genes Dev. 14 (2000) 163–176.
[9] J.S. Munger, X. Huang, H. Kawakatsu, M.J. Grifﬁths, S.L. Dalton, J. Wu, J.F. Pittet, N.
Kaminski, C. Garat, M.A. Matthay, D.B. Rifkin, D. Sheppard, The integrin alpha V
beta 6 binds and activates latent TGF beta 1: a mechanism for regulating
pulmonary inﬂammation and ﬁbrosis, Cell 96 (1999) 319–328.
[10] D. Mu, S. Cambier, L. Fjellbirkeland, J.L. Baron, J.S. Munger, H. Kawakatsu, D.
Sheppard, V.C. Broaddus, S.L. Nishimura, The integrin alpha(V)beta8 mediates
epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1,
J. Cell Biol. 157 (2002) 493–507.
[11] P.J. Wipff, B. Hinz, Integrins and the activation of latent transforming growth
factor beta1 — an intimate relationship, Eur. J. Cell Biol. 87 (2008) 601–615.
[12] R.M. Lyons, J. Keski-Oja, H.L. Moses, Proteolytic activation of latent transforming
growth factor-beta from ﬁbroblast-conditioned medium, J. Cell Biol. 106 (1988)
1659–1665.
[13] J.E.Murphy-Ullrich, M. Poczatek, Activation of latent TGF-beta by thrombospondin-
1: mechanisms and physiology, Cytokine Growth Factor Rev. 11 (2000) 59–69.
[14] R. Derynck, Y.E. Zhang, Smad-dependent and Smad-independent pathways in
TGF-beta family signalling, Nature 425 (2003) 577–584.
[15] L. Chen, C. Klass, A. Woods, Syndecan-2 regulates transforming growth factor-
beta signaling, J. Biol. Chem. 279 (2004) 15715–15718.
[16] H.J. You, M.W. Bruinsma, T. How, J.H. Ostrander, G.C. Blobe, The type III TGF-beta
receptor signals through both Smad3 and the p38 MAP kinase pathways to
contribute to inhibition of cell proliferation, Carcinogenesis 28 (2007) 2491–2500.
[17] J. Massague, How cells read TGF-beta signals, Nat. Rev., Mol. Cell Biol. 1 (2000)
169–178.
[18] D. Wotton, J. Massague, Smad transcriptional corepressors in TGF beta family
signaling, Curr. Top. Microbiol. Immunol. 254 (2001) 145–164.
[19] J. Massague, Integration of Smad and MAPK pathways: a link and a linker
revisited, Genes Dev. 17 (2003) 2993–2997.
[20] I. Yakymovych, D.P. Ten, C.H. Heldin, S. Souchelnytskyi, Regulation of Smad
signaling by protein kinase C, FASEB J. 15 (2001) 553–555.
[21] A.R. Conery, Y. Cao, E.A. Thompson, C.M. Townsend Jr., T.C. Ko, K. Luo, Akt
interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced
apoptosis, Nat. Cell Biol. 6 (2004) 366–372.
[22] A. Masszi, C.C. Di, G. Sirokmany, W.T. Arthur, O.D. Rotstein, J. Wang, C.A.
McCulloch, L. Rosivall, I. Mucsi, A. Kapus, Central role for Rho in TGF-beta1-
induced alpha-smooth muscle actin expression during epithelial–mesenchymal
transition, Am. J. Physiol. Renal Physiol. 284 (2003) F911–F924.
[23] N. Muller, A. Reinacher-Schick, S. Baldus, H.J. van, G. Berx, A. Baar, R.F. van, W.
Schmiegel, I. Schwarte-Waldhoff, Smad4 induces the tumor suppressor E-cadherin
and P-cadherin in colon carcinoma cells, Oncogene 21 (2002) 6049–6058.
[24] H. Wang, V. Radjendirane, K.K. Wary, S. Chakrabarty, Transforming growth factor
beta regulates cell–cell adhesion through extracellular matrix remodeling and
activation of focal adhesion kinase in human colon carcinoma Moser cells,
Oncogene 23 (2004) 5558–5561.
[25] V.J. Thannickal, D.Y. Lee, E.S. White, Z. Cui, J.M. Larios, R. Chacon, J.C. Horowitz,
R.M. Day, P.E. Thomas, Myoﬁbroblast differentiation by transforming growth
factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion
kinase, J. Biol. Chem. 278 (2003) 12384–12389.
[26] X. Shi-Wen, S.K. Parapuram, D. Pala, Y. Chen, D.E. Carter, M. Eastwood, C.P.
Denton, D.J. Abraham, A. Leask, Requirement of transforming growth factor beta-
activated kinase 1 for transforming growth factor beta-induced alpha-smooth
muscle actin expression and extracellular matrix contraction in ﬁbroblasts,
Arthritis Rheum. 60 (2009) 234–241.
[27] S. Liu, S.W. Xu, L. Kennedy, D. Pala, Y. Chen, M. Eastwood, D.E. Carter, C.M. Black,
D.J. Abraham, A. Leask, FAK is required for TGFbeta-induced JNK phosphorylation
in ﬁbroblasts: implications for acquisition of a matrix-remodeling phenotype,
Mol. Biol. Cell 18 (2007) 2169–2178.
[28] H. Hayashi, S. Abdollah, Y. Qiu, J. Cai, Y.Y. Xu, B.W. Grinnell, M.A. Richardson, J.N.
Topper, M.A. Gimbrone, J.L. Wrana, D. Falb, The MAD-related protein Smad7
associates with the TGFbeta receptor and functions as an antagonist of TGFbeta
signaling, Cell 89 (1997) 1165–1173.
[29] A. Nakao, M. Afrakhte, A. Moren, T. Nakayama, J.L. Christian, R. Heuchel, S. Itoh, M.
Kawabata, N.E. Heldin, C.H. Heldin, D.P. Ten, Identiﬁcation of Smad7, a TGFbeta-
inducible antagonist of TGF-beta signalling, Nature 389 (1997) 631–635.
[30] G. Salvador, R. Sanmarti, B. Gil-Torregrosa, A. Garcia-Peiro, J.R. Rodriguez-Cros,
J.D. Canete, Synovial vascular patterns and angiogenic factors expression in
synovial tissue and serum of patients with rheumatoid arthritis, Rheumatology.
(Oxford) 45 (2006) 966–971.
753D. Pohlers et al. / Biochimica et Biophysica Acta 1792 (2009) 746–756[31] S.Y. Kim, S.W. Han, G.W. Kim, J.M. Lee, Y.M. Kang, TGF-beta1 polymorphism
determines the progression of joint damage in rheumatoid arthritis, Scand. J.
Rheumatol. 33 (2004) 389–394.
[32] H. Cheon, S.J. Yu, D.H. Yoo, I.J. Chae, G.G. Song, J. Sohn, Increased expression of
pro-inﬂammatory cytokines and metalloproteinase-1 by TGF-beta1 in synovial
ﬁbroblasts from rheumatoid arthritis and normal individuals, Clin. Exp.
Immunol. 127 (2002) 547–552.
[33] Y. Yamanishi, D.L. Boyle, M. Clark, R.A. Maki, M.D. Tortorella, E.C. Arner, G.S.
Firestein, Expression and regulation of aggrecanase in arthritis: the role of
TGF-beta, J. Immunol. 168 (2002) 1405–1412.
[34] J.A. Hamilton, D.S. Piccoli, T. Leizer, D.M. Butler, M. Croatto, A.K. Royston,
Transforming growth factor beta stimulates urokinase-type plasminogen
activator and DNA synthesis, but not prostaglandin E2 production, in human
synovial ﬁbroblasts, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7180–7184.
[35] F. Taketazu, M. Kato, A. Gobl, H. Ichijo, P. ten Dijke, J. Itoh, M. Kyogoku, J.
Ronnelid, K. Miyazono, C.H. Heldin, Enhanced expression of transforming
growth factor-beta s and transforming growth factor-beta type II receptor in the
synovial tissues of patients with rheumatoid arthritis, Lab. Invest. 70 (1994)
620–630.
[36] C.Q. Chu, M. Field, E. Abney, R.Q. Zheng, S. Allard, M. Feldmann, R.N. Maini,
Transforming growth factor-beta 1 in rheumatoid synovial membrane and
cartilage/pannus junction, Clin. Exp. Immunol. 86 (1991) 380–386.
[37] Z. Szekanecz, G.K. Haines, L.A. Harlow, M.R. Shah, T.W. Fong, R. Fu, S.J. Lin, G.
Rayan, A.E. Koch, Increased synovial expression of transforming growth factor
(TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible
interactions in the pathogenesis of the disease, Clin. Immunol. Immunopathol. 76
(1995) 187–194.
[38] D.H. Goddard, S.L. Grossman, W.V. Williams, D.B. Weiner, J.L. Gross, K. Eidsvoog,
J.R. Dasch, Regulation of synovial cell growth. Coexpression of transforming
growth factor beta and basic ﬁbroblast growth factor by cultured synovial cells,
Arthritis Rheum. 35 (1992) 1296–1303.
[39] R. Fava, N. Olsen, J. Keski-Oja, H. Moses, T. Pincus, Active and latent forms of
transforming growth factor beta activity in synovial effusions, J. Exp. Med. 169
(1989) 291–296.
[40] D. Pohlers, A. Beyer, D. Koczan, T. Wilhelm, H.J. Thiesen, R.W. Kinne, Constitutive
upregulation of the transforming growth factor-beta pathway in rheumatoid
arthritis synovial ﬁbroblasts, Arthritis Res. Ther. 9 (2007) R59.
[41] A. Müssener, K. Funa, S. Kleinau, L. Klareskog, Dynamic expression of trans-
forming growth factor-betas (TGF-beta) and their type I and type II receptors in
the synovial tissue of arthritic rats, Clin. Exp. Immunol. 107 (1997) 112–119.
[42] J.B. Allen, C.L. Manthey, A.R. Hand, K. Ohura, L. Ellingsworth, S.M. Wahl, Rapid
onset synovial inﬂammation and hyperplasia induced by transforming growth
factor beta, J. Exp. Med. 171 (1990) 231–247.
[43] S.M. Wahl, J.B. Allen, G.L. Costa, H.L. Wong, J.R. Dasch, Reversal of acute and
chronic synovial inﬂammation by anti-transforming growth factor beta, J. Exp.
Med. 177 (1993) 225–230.
[44] Z. Mi, S.C. Ghivizzani, E. Lechman, J.C. Glorioso, C.H. Evans, P.D. Robbins, Adverse
effects of adenovirus-mediated gene transfer of human transforming growth
factor beta 1 into rabbit knees, Arthritis Res. Ther. 5 (2003) R132–R139.
[45] M. Sakuma, K. Hatsushika, K. Koyama, R. Katoh, T. Ando, Y. Watanabe, M. Wako,
M. Kanzaki, S. Takano, H. Sugiyama, Y. Hamada, H. Ogawa, K. Okumura, A. Nakao,
TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes
and prevents the arthritis induced by type II collagen antibody, Int. Immunol. 19
(2007) 117–126.
[46] M.E. Brandes, J.B. Allen, Y. Ogawa, S.M. Wahl, Transforming growth factor beta 1
suppresses acute and chronic arthritis in experimental animals, J. Clin. Invest. 87
(1991) 1108–1113.
[47] C. Schramm, J. Kriegsmann, M. Protschka, S. Huber, T. Hansen, E. Schmitt, P.R.
Galle, M. Blessing, Susceptibility to collagen-induced arthritis is modulated by
TGFbeta responsiveness of T cells, Arthritis Res. Ther. 6 (2004) R114–R119.
[48] Y. Chernajovsky, G. Adams, K. Triantaphyllopoulos, M.F. Ledda, O.L. Podhajcer,
Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease
in a collagen-induced arthritis model, Gene Ther. 4 (1997) 553–559.
[49] F.N. Ziyadeh, K. Sharma, M. Ericksen, G. Wolf, Stimulation of collagen gene
expression and protein synthesis in murine mesangial cells by high glucose is
mediated by autocrine activation of transforming growth factor-beta, J. Clin.
Invest. 93 (1994) 536–542.
[50] F.N. Ziyadeh, Evidence for the involvement of transforming growth factor-β in
the pathogenesis of diabetic kidney disease: are Koch's postulates fulﬁlled? Curr.
Pract. Med. 1 (1998) 87–89.
[51] G. Wolf, K. Sharma, Y. Chen, M. Ericksen, F.N. Ziyadeh, High glucose-induced
proliferation in mesangial cells is reversed by autocrine TGF-beta, Kidney Int. 42
(1992) 647–656.
[52] G. Wolf, E. Mueller, R.A. Stahl, F.N. Ziyadeh, Angiotensin II-induced hypertrophy
of cultured murine proximal tubular cells is mediated by endogenous
transforming growth factor-beta, J. Clin. Invest. 92 (1993) 1366–1372.
[53] T. Yamamoto, T. Nakamura, N.A. Noble, E. Ruoslahti, W.A. Border, Expression of
transforming growth factor beta is elevated in human and experimental diabetic
nephropathy, Proc. Natl. Acad Sci. U. S. A 90 (1993) 1814–1818.
[54] K. Sharma, F.N. Ziyadeh, Renal hypertrophy is associated with upregulation of
TGF-beta 1 gene expression in diabetic BB rat and NODmouse, Am. J. Physiol. 267
(1994) F1094–01.
[55] S.W. Hong, M. Isono, S. Chen, M.C. Iglesias-de la Cruz, D.C. Han, F.N. Ziyadeh,
Increased glomerular and tubular expression of transforming growth factor-
beta1, its type II receptor, and activation of the Smad signaling pathway in the
db/db mouse, Am. J. Pathol. 158 (2001) 1653–1663.[56] K. Sharma, Y. Jin, J. Guo, F.N. Ziyadeh, Neutralization of TGF-beta by anti-TGF-
beta antibody attenuates kidney hypertrophy and the enhanced extracellular
matrix gene expression in STZ-induced diabetic mice, Diabetes 45 (1996)
522–530.
[57] F.N. Ziyadeh, B.B. Hoffman, D.C. Han, M.C. Iglesias-de la Cruz, S.W. Hong, M.
Isono, S. Chen, T.A. McGowan, K. Sharma, Long-term prevention of renal
insufﬁciency, excess matrix gene expression, and glomerular mesangial
matrix expansion by treatment with monoclonal antitransforming growth
factor-beta antibody in db/db diabetic mice, Proc. Natl. Acad Sci. U. S. A. 97 (2000)
8015–8020.
[58] M. Isono, A. Mogyorosi, D.C. Han, B.B. Hoffman, F.N. Ziyadeh, Stimulation of
TGF-beta type II receptor by high glucose inmousemesangial cells and in diabetic
kidney, Am. J. Physiol., Renal Physiol. 278 (2000) F830–F838.
[59] G. Wolf, G. Zahner, R. Schroeder, R.A. Stahl, Transforming growth factor beta
mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in
cultured murine proximal tubular cells, Nephrol. Dial. Transplant. 11 (1996)
263–269.
[60] D.C. Han, B.B. Hoffman, S.W. Hong, J. Guo, F.N. Ziyadeh, Therapy with antisense
TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in
diabetic mice, Am. J. Physiol., Renal Physiol. 278 (2000) F628–F634.
[61] M. Abbate, C. Zoja, M. Morigi, D. Rottoli, S. Angioletti, S. Tomasoni, C. Zanchi, L.
Longaretti, R. Donadelli, G. Remuzzi, Transforming growth factor-beta1 is up-
regulated by podocytes in response to excess intraglomerular passage of
proteins: a central pathway in progressive glomerulosclerosis, Am. J. Pathol.
161 (2002) 2179–2193.
[62] R.E. Gilbert, A. Cox, L.L. Wu, T.J. Allen, U.L. Hulthen, G. Jerums, M.E. Cooper,
Expression of transforming growth factor-beta1 and type IV collagen in the renal
tubulointerstitium in experimental diabetes: effects of ACE inhibition, Diabetes
47 (1998) 414–422.
[63] G.Wolf, S. Chen, F.N. Ziyadeh, From the periphery of the glomerular capillary wall
toward the center of disease: podocyte injury comes of age in diabetic
nephropathy, Diabetes 54 (2005) 1626–1634.
[64] D.T. Wu, M. Bitzer, W. Ju, P. Mundel, E.P. Bottinger, TGF-beta concentration
speciﬁes differential signaling proﬁles of growth arrest/differentiation and
apoptosis in podocytes, J. Am. Soc. Nephrol. 16 (2005) 3211–3221.
[65] S.L. Dallas, K. Miyazono, T.M. Skerry, G.R. Mundy, L.F. Bonewald, Dual role for
the latent transforming growth factor-beta binding protein in storage of latent
TGF-beta in the extracellular matrix and as a structural matrix protein, J. Cell
Biol. 131 (1995) 539–549.
[66] M. Isono, S. Chen, S.W. Hong, M.C. Iglesias-de la Cruz, F.N. Ziyadeh, Smad pathway
is activated in the diabetic mouse kidney and Smad3mediates TGF-beta-induced
ﬁbronectin in mesangial cells, Biochem. Biophys. Res. Commun. 296 (2002)
1356–1365.
[67] Y. Furuse, N. Hashimoto, M.Maekawa, Y. Toyama, A. Nakao, I. Iwamoto, K. Sakurai,
Y. Suzuki, K. Yagui, S. Yuasa, K. Toshimori, Y. Saito, Activation of the Smad
pathway in glomeruli from a spontaneously diabetic rat model, OLETF rats,
Nephron, Exp. Nephrol. 98 (2004) e100–e108.
[68] M. Schiffer, L.E. Schiffer, A. Gupta, A.S. Shaw, I.S. Roberts, P. Mundel, E.P. Bottinger,
Inhibitory smads and tgf-Beta signaling in glomerular cells, J. Am. Soc. Nephrol.
13 (2002) 2657–2666.
[69] M. Cordenonsi, M. Montagner, M. Adorno, L. Zacchigna, G. Martello, A. Mamidi, S.
Soligo, S. Dupont, S. Piccolo, Integration of TGF-beta and Ras/MAPK signaling
through p53 phosphorylation, Science 315 (2007) 840–843.
[70] M. Schiffer, P. Mundel, A.S. Shaw, E.P. Bottinger, A novel role for the adaptor
molecule CD2-associated protein in transforming growth factor-beta-induced
apoptosis, J. Biol. Chem. 279 (2004) 37004–37012.
[71] K. Yoshioka, T. Takemura, K. Murakami, M. Okada, S. Hino, H. Miyamoto, S. Maki,
Transforming growth factor-beta protein and mRNA in glomeruli in normal and
diseased human kidneys, Lab. Invest. 68 (1993) 154–163.
[72] T. Yamamoto, N.A. Noble, A.H. Cohen, C.C. Nast, A. Hishida, L.I. Gold, W.A. Border,
Expression of transforming growth factor-beta isoforms in human glomerular
diseases, Kidney Int. 49 (1996) 461–469.
[73] K. Sharma, F.N. Ziyadeh, B. Alzahabi, T.A. McGowan, S. Kapoor, B.R. Kurnik,
P.B. Kurnik, L.S. Weisberg, Increased renal production of transforming growth
factor-beta1 in patients with type II diabetes, Diabetes 46 (1997) 854–859.
[74] S. Tsakas, D.S. Goumenos, Accurate measurement and clinical signiﬁcance of
urinary transforming growth factor-beta1, Am. J. Nephrol. 26 (2006) 186–193.
[75] K. Sharma, B.O. Eltayeb, T.A. McGowan, S.R. Dunn, B. Alzahabi, R. Rohde, F.N.
Ziyadeh, E.J. Lewis, Captopril-induced reduction of serum levels of transforming
growth factor-beta1 correlateswith long-term renoprotection in insulin-dependent
diabetic patients, Am. J. Kidney Dis. 34 (1999) 818–823.
[76] M.W. Babyatsky, G. Rossiter, D.K. Podolsky, Expression of transforming growth
factors alpha and beta in colonic mucosa in inﬂammatory bowel disease, Gastro-
enterology 110 (1996) 975–984.
[77] G.C. Blobe, W.P. Schiemann, H.F. Lodish, Role of transforming growth factor beta
in human disease, N. Engl. J. Med. 342 (2000) 1350–1358.
[78] A. Izcue, J.L. Coombes, F. Powrie, Regulatory T cells suppress systemic and mucosal
immune activation to control intestinal inﬂammation, Immunol. Rev. 212 (2006)
256–271.
[79] L. Gorelik, S. Constant, R.A. Flavell, Mechanism of transforming growth factor
beta-induced inhibition of T helper type 1 differentiation, J. Exp. Med.195 (2002)
1499–1505.
[80] A.B. Kulkarni, C.G. Huh, D. Becker, A. Geiser, M. Lyght, K.C. Flanders, A.B. Roberts,
M.B. Sporn, J.M. Ward, S. Karlsson, Transforming growth factor beta 1 null
mutation in mice causes excessive inﬂammatory response and early death, Proc.
Natl. Acad. Sci. U. S. A 90 (1993) 770–774.
754 D. Pohlers et al. / Biochimica et Biophysica Acta 1792 (2009) 746–756[81] M. Boirivant, I.J. Fuss, A. Chu, W. Strober, Oxazolone colitis: A murine model of
T helper cell type 2 colitis treatable with antibodies to interleukin 4, J. Exp. Med.
188 (1998) 1929–1939.
[82] M.F. Neurath, S. Pettersson, K.H. Meyer zum Buschenfelde, W. Strober, Local
administration of antisense phosphorothioate oligonucleotides to the p65
subunit of NF-kappa B abrogates established experimental colitis in mice, Nat.
Med. 2 (1996) 998–1004.
[83] F. Powrie, J. Carlino, M.W. Leach, S. Mauze, R.L. Coffman, A critical role for
transforming growth factor-beta but not interleukin 4 in the suppression of
T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells, J. Exp. Med. 183
(1996) 2669–2674.
[84] E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner, V.K.
Kuchroo, Reciprocal developmental pathways for the generation of pathogenic
effector TH17 and regulatory T cells, Nature 441 (2006) 235–238.
[85] P.R. Mangan, L.E. Harrington, D.B. O'Quinn, W.S. Helms, D.C. Bullard, C.O.
Elson, R.D. Hatton, S.M. Wahl, T.R. Schoeb, C.T. Weaver, Transforming growth
factor-beta induces development of the T(H)17 lineage, Nature 441 (2006)
231–234.
[86] M. Veldhoen, R.J. Hocking, C.J. Atkins, R.M. Locksley, B. Stockinger, TGFbeta in the
context of an inﬂammatory cytokine milieu supports de novo differentiation of
IL-17-producing T cells, Immunity 24 (2006) 179–189.
[87] V. Santarlasci, L. Maggi, M. Capone, F. Frosali, V. Querci, P.R. De, F. Liotta, L. Cosmi,
E. Maggi, S. Romagnani, F. Annunziato, TGF-beta indirectly favors the development
of human Th17 cells by inhibiting Th1 cells, Eur. J. Immunol. 39 (2009) 207–215.
[88] E. Volpe, N. Servant, R. Zollinger, S.I. Bogiatzi, P. Hupe, E. Barillot, V. Soumelis, A
critical function for transforming growth factor-beta, interleukin 23 and
proinﬂammatory cytokines in driving and modulating human T(H)-17
responses, Nat. Immunol. 9 (2008) 650–657.
[89] L. Yang, D.E. Anderson, C. Baecher-Allan, W.D. Hastings, E. Bettelli, M. Oukka, V.K.
Kuchroo, D.A. Haﬂer, IL-21 and TGF-beta are required for differentiation of
human T(H)17 cells, Nature 454 (2008) 350–352.
[90] X. Yang, J.J. Letterio, R.J. Lechleider, L. Chen, R. Hayman, H. Gu, A.B. Roberts, C.
Deng, Targeted disruption of SMAD3 results in impaired mucosal immunity and
diminished T cell responsiveness to TGF-beta, EMBO J. 18 (1999) 1280–1291.
[91] G. Monteleone, A. Kumberova, N.M. Croft, C. McKenzie, H.W. Steer, T.T.
MacDonald, Blocking Smad7 restores TGF-beta1 signaling in chronic inﬂamma-
tory bowel disease, J. Clin. Invest. 108 (2001) 601–609.
[92] N.A. Bhowmick, M. Ghiassi, A. Bakin, M. Aakre, C.A. Lundquist, M.E. Engel, C.L.
Arteaga, H.L. Moses, Transforming growth factor-beta1 mediates epithelial to
mesenchymal transdifferentiation through a RhoA-dependent mechanism, Mol.
Biol. Cell 12 (2001) 27–36.
[93] V. Ellenrieder, S.F. Hendler, W. Boeck, T. Seufferlein, A. Menke, C. Ruhland, G.
Adler, T.M. Gress, Transforming growth factor beta1 treatment leads to an
epithelial–mesenchymal transdifferentiation of pancreatic cancer cells requiring
extracellular signal-regulated kinase 2 activation, Cancer Res. 61 (2001)
4222–4228.
[94] K. Fujimoto, H. Sheng, J. Shao, R.D. Beauchamp, Transforming growth factor-
beta1 promotes invasiveness after cellular transformation with activated Ras in
intestinal epithelial cells, Exp. Cell Res. 266 (2001) 239–249.
[95] K. Lehmann, E. Janda, C.E. Pierreux, M. Rytomaa, A. Schulze, M. McMahon, C.S.
Hill, H. Beug, J. Downward, Raf induces TGFbeta production while blocking its
apoptotic but not invasive responses: a mechanism leading to increased
malignancy in epithelial cells, Genes Dev. 14 (2000) 2610–2622.
[96] M. Oft, K.H. Heider, H. Beug, TGFbeta signaling is necessary for carcinoma cell
invasiveness and metastasis, Curr. Biol. 8 (1998) 1243–1252.
[97] G. Portella, S.A. Cumming, J. Liddell, W. Cui, H. Ireland, R.J. Akhurst, A. Balmain,
Transforming growth factor beta is essential for spindle cell conversion of mouse
skin carcinoma in vivo: implications for tumor invasion, Cell Growth Differ. 9
(1998) 393–404.
[98] A.M. Arias, Epithelial mesenchymal interactions in cancer and development, Cell
105 (2001) 425–431.
[99] J.P. Thiery, D. Chopin, Epithelial cell plasticity in development and tumor
progression, Cancer Metastasis Rev. 18 (1999) 31–42.
[100] R. Kalluri, E.G. Neilson, Epithelial–mesenchymal transition and its implications
for ﬁbrosis, J. Clin. Invest 112 (2003) 1776–1784.
[101] S. Saika, S. Kono-Saika, Y. Ohnishi, M. Sato, Y. Muragaki, A. Ooshima, K.C. Flanders,
J. Yoo, M. Anzano, C.Y. Liu, W.W. Kao, A.B. Roberts, Smad3 signaling is required for
epithelial–mesenchymal transition of lens epithelium after injury, Am. J. Pathol.
164 (2004) 651–663.
[102] M. Sato, Y. Muragaki, S. Saika, A.B. Roberts, A. Ooshima, Targeted disruption of
TGF-beta1/Smad3 signaling protects against renal tubulointerstitial ﬁbrosis
induced by unilateral ureteral obstruction, J. Clin. Invest 112 (2003) 1486–1494.
[103] P.L. Beck, D.K. Podolsky, Growth factors in inﬂammatory bowel disease, Inﬂamm.
Bowel Dis. 5 (1999) 44–60.
[104] C. Fiocchi, TGF-beta/Smad signaling defects in inﬂammatory bowel disease:
mechanisms and possible novel therapies for chronic inﬂammation, J. Clin. Invest
108 (2001) 523–526.
[105] K.B. Hahm, Y.H. Im, T.W. Parks, S.H. Park, S. Markowitz, H.Y. Jung, J. Green, S.J. Kim,
Loss of transforming growth factor beta signalling in the intestine contributes to
tissue injury in inﬂammatory bowel disease, Gut 49 (2001) 190–198.
[106] H. Matthes, H. Herbst, D. Schuppan, A. Stallmach, S. Milani, H. Stein, E.O. Riecken,
Cellular localization of procollagen gene transcripts in inﬂammatory bowel
diseases, Gastroenterology 102 (1992) 431–442.
[107] A. Stallmach, D. Schuppan, H.H. Riese, H. Matthes, E.O. Riecken, Increased
collagen type III synthesis by ﬁbroblasts isolated from strictures of patients with
Crohn's disease, Gastroenterology 102 (1992) 1920–1929.[108] I.C. Lawrance, L. Maxwell, W. Doe, Inﬂammation location, but not type,
determines the increase in TGF-beta1 and IGF-1 expression and collagen
deposition in IBD intestine, Inﬂamm. Bowel. Dis. 7 (2001) 16–26.
[109] J.B. Pucilowska, K.L. Williams, P.K. Lund, Fibrogenesis. IV. Fibrosis and
inﬂammatory bowel disease: cellular mediators and animal models, Am. J.
Physiol.: Gasterointest. Liver Physiol. 279 (2000) G653–G659.
[110] L.M. Liem, W.E. Fibbe, H.C. van Houwelingen, E. Goulmy, Serum transforming
growth factor-beta1 levels in bone marrow transplant recipients correlate with
blood cell counts and chronic graft-versus-host disease, Transplantation 67
(1999) 59–65.
[111] M. Stahle-Backdahl, J. Maim, B. Veress, C. Benoni, K. Bruce, A. Egesten, Increased
presence of eosinophilic granulocytes expressing transforming growth factor-
beta1 in collagenous colitis, Scand. J. Gastroenterol. 35 (2000) 742–746.
[112] J. Wang, H. Zheng, C.C. Sung, K.K. Richter, M. Hauer-Jensen, Cellular sources of
transforming growth factor-beta isoforms in early and chronic radiation
enteropathy, Am. J. Pathol. 153 (1998) 1531–1540.
[113] F.F. di Mola, H. Friess, A. Scheuren, S.P. Di, H. Graber, B. Egger, A. Zimmermann, M.
Korc, M.W. Buchler, Transforming growth factor-betas and their signaling
receptors are coexpressed in Crohn's disease, Ann. Surg. 229 (1999) 67–75.
[114] B.C. McKaig, K. Hughes, P.J. Tighe, Y.R. Mahida, Differential expression of TGF-beta
isoforms by normal and inﬂammatory bowel disease intestinal myoﬁbroblasts,
Am. J. Physiol., Cell Physiol. 282 (2002) C172–C182.
[115] A. Leask, D.J. Abraham, TGF-beta signaling and the ﬁbrotic response, FASEB J. 18
(2004) 816–827.
[116] G. Monteleone, B.G. Del Vecchio, I. Monteleone, D. Fina, R. Caruso, V. Gioia, S.
Ballerini, G. Federici, S. Bernardini, F. Pallone, T.T. MacDonald, Post-transcriptional
regulation of Smad7 in the gut of patients with inﬂammatory bowel disease,
Gastroenterology 129 (2005) 1420–1429.
[117] G. Monteleone, B.G. Del Vecchio, G. Palmieri, P. Vavassori, I. Monteleone, A.
Colantoni, S. Battista, L.G. Spagnoli, M. Romano, M. Borrelli, T.T. MacDonald, F.
Pallone, Induction and regulation of Smad7 in the gastric mucosa of patients with
Helicobacter pylori infection, Gastroenterology 126 (2004) 674–682.
[118] K. Randall, J.E. Coggle, Expression of transforming growth factor-beta 1 in
mouse skin during the acute phase of radiation damage, Int. J. Radiat. Biol. 68
(1995) 301–309.
[119] K. Randall, J.E. Coggle, Long-term expression of transforming growth factor TGF
beta 1 in mouse skin after localized beta-irradiation, Int. J. Radiat. Biol. 70
(1996) 351–360.
[120] M. Martin, J.L. Lefaix, P. Pinton, F. Crechet, F. Daburon, Temporal modulation of
TGF-beta 1 and beta-actin gene expression in pig skin andmuscular ﬁbrosis after
ionizing radiation, Radiat. Res. 134 (1993) 63–70.
[121] M. Martin, J. Lefaix, S. Delanian, TGF-beta1 and radiation ﬁbrosis: a master
switch and a speciﬁc therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47
(2000) 277–290.
[122] S. Schultze-Mosgau, F. Wehrhan, G. Grabenbauer, K. Amann, M. Radespiel-Troger,
F.W. Neukam, F. Rodel, Transforming growth factor beta1 and beta2 (TGFbeta2/
TGFbeta2) proﬁle changes in previously irradiated free ﬂap beds, Head Neck 24
(2002) 33–41.
[123] S. Schultze-Mosgau, F. Wehrhan, F. Rodel, K. Amann, M. Radespiel-Troger, G.G.
Grabenbauer, Transforming growth factor-beta receptor-II up-regulation during
wound healing in previously irradiated graft beds in vivo, Wound Repair Regen.
11 (2003) 297–305.
[124] S. Schultze-Mosgau, M.A. Blaese, G. Grabenbauer, F. Wehrhan, J. Kopp, K. Amann,
H.P. Rodemann, F. Rodel, Smad-3 and Smad-7 expression following anti-
transforming growth factor beta 1 (TGFbeta1)-treatment in irradiated rat tissue,
Radiother. Oncol. 70 (2004) 249–259.
[125] W.A. Border, N.A. Noble, Transforming growth factor beta in tissue ﬁbrosis, N.
Engl. J. Med. 331 (1994) 1286–1292.
[126] S. Schultze-Mosgau, J. Kopp, M. Thorwarth, F. Rodel, I. Melnychenko, G.G.
Grabenbauer, K. Amann, F. Wehrhan, Plasminogen activator inhibitor-I-related
regulation of procollagen I (alpha1 and alpha2) by antitransforming growth
factor-beta1 treatment during radiation-impaired wound healing, Int. J. Radiat.
Oncol. Biol. Phys. 64 (2006) 280–288.
[127] D. Ulrich, F. Lichtenegger, M. Eblenkamp, D. Repper, N. Pallua, Matrix
metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal
propeptide of procollagen type III, and hyaluronan in sera and tissue of patients
with capsular contracture after augmentation with Trilucent breast implants,
Plast. Reconstr. Surg. 114 (2004) 229–236.
[128] J.A. Schiro, B.M. Chan, W.T. Roswit, P.D. Kassner, A.P. Pentland, M.E. Hemler, A.Z.
Eisen, T.S. Kupper, Integrin alpha 2 beta 1 (VLA-2) mediates reorganization and
contraction of collagen matrices by human cells, Cell 67 (1991) 403–410.
[129] P.D. Arora, N. Narani, C.A. McCulloch, The compliance of collagen gels regulates
transforming growth factor-beta induction of alpha-smooth muscle actin in
ﬁbroblasts, Am. J. Pathol. 154 (1999) 871–882.
[130] M.K. Tibbs, Wound healing following radiation therapy: a review, Radiother.
Oncol. 42 (1997) 99–106.
[131] R. Tokarek, E.F. Bernstein, F. Sullivan, J. Uitto, J.B. Mitchell, Effect of therapeutic
radiation on wound healing, Clin. Dermatol. 12 (1994) 57–70.
[132] S. Schultze-Mosgau, G.G. Grabenbauer, M. Radespiel-Troger, J. Wiltfang, J. Ries,
F.W. Neukam, F. Rodel, Vascularization in the transition area between free
grafted soft tissues and pre-irradiated graft bed tissues following preoperative
radiotherapy in the head and neck region, Head Neck 24 (2002) 42–51.
[133] C. Li, P.B. Wilson, E. Levine, J. Barber, A.L. Stewart, S. Kumar, TGF-beta1 levels
in pre-treatment plasma identify breast cancer patients at risk of developing
post-radiotherapy ﬁbrosis, Int. J. Cancer 84 (1999) 155–159.
[134] A.M. Feldman, D. McNamara, N. Myocarditis, Engl. J. Med. 343 (2000) 1388–1398.
755D. Pohlers et al. / Biochimica et Biophysica Acta 1792 (2009) 746–756[135] B. Maisch, A. Richter, A. Sandmoller, I. Portig, S. Pankuweit, Inﬂammatory dilated
cardiomyopathy (DCMI), Herz 30 (2005) 535–544.
[136] L. Rey, V. Lambert, P. Wattre, L. Andreoletti, Detection of enteroviruses ribo-
nucleic acid sequences in endomyocardial tissue from adult patients with chro-
nic dilated cardiomyopathy by a rapid RT-PCR and hybridization assay, J. Med.
Virol. 64 (2001) 133–140.
[137] J.L. Melnik, Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and
newer enteroviruses, in: B.N. Fields, D.M. Knipe, P.M. Howley (Eds.), Virology,
Lippincott-Raven, Philadelphia, 1996, pp. 655–712.
[138] N.R. Rose, D.A. Neumann, A. Herskovitz, Coxsackievirus myocarditis, in: G.H.
Stollerman, J.T. LaMont, J.J. Leonard, M.D. Siperstein (Eds.), Advances in Internal
Medicine, Mosby-Year Book, Inc., St.Louis, 1992, pp. 411–429.
[139] B. Maisch, H. Rupp, [Myocardial ﬁbrosis: a cardiopathophysiologic Janus head],
Herz 31 (2006) 260–268.
[140] U. Eismann, M. Sommer, H. Kosmehl, D. Appenroth, C. Fleck, G. Stein, Fibronectin
splice variants—prognostic markers for the stage of renal interstitial ﬁbrosis in
the rat, Nephron 92 (2002) 379–388.
[141] A. Tamura, S. Kusachi, K. Nogami, A. Yamanishi, Y. Kajikawa, S. Hirohata, T. Tsuji,
Tenascin expression in endomyocardial biopsy specimens in patients with
dilated cardiomyopathy: distribution along margin of ﬁbrotic lesions, Heart 75
(1996) 291–294.
[142] S. Rosenkranz, M. Flesch, K. Amann, C. Haeuseler, H. Kilter, U. Seeland, K.D.
Schluter, M. Bohm, Alterations of beta-adrenergic signaling and cardiac hyper-
trophy in transgenic mice overexpressing TGF-beta(1), Am. J. Physiol. Heart Circ.
Physiol. 283 (2002) H1253–H1262.
[143] K. Isoda, Y. Kamezawa, N. Tada, M. Sato, F. Ohsuzu, Myocardial hypertrophy in
transgenic mice overexpressing human interleukin 1alpha, J. Card. Fail. 7 (2001)
355–364.
[144] D. Bryant, L. Becker, J. Richardson, J. Shelton, F. Franco, R. Peshock, M. Thompson,
B. Giroir, Cardiac failure in transgenic mice with myocardial expression of tumor
necrosis factor-alpha, Circulation 97 (1998) 1375–1381.
[145] T. Kubota, C.F. McTiernan, C.S. Frye, A.J. Demetris, A.M. Feldman, Cardiac-speciﬁc
overexpression of tumor necrosis factor-alpha causes lethal myocarditis in
transgenic mice, J. Card. Fail. 3 (1997) 117–124.
[146] A. Ponten, X. Li, P. Thoren, K. Aase, T. Sjoblom, A. Ostman, U. Eriksson, Transgenic
overexpression of platelet-derived growth factor-C in the mouse heart induces
cardiac ﬁbrosis, hypertrophy, and dilated cardiomyopathy, Am. J. Pathol. 163
(2003) 673–682.
[147] A. Ponten, E.B. Folestad, K. Pietras, U. Eriksson, Platelet-derived growth factor D
induces cardiac ﬁbrosis and proliferation of vascular smooth muscle cells in
heart-speciﬁc transgenic mice, Circ. Res. 97 (2005) 1036–1045.
[148] B. Gluck, M. Schmidtke, I. Merkle, A. Stelzner, D. Gemsa, Persistent expression of
cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice, J. Mol.
Cell Cardiol. 33 (2001) 1615–1626.
[149] M. Schmidtke, B. Gluck, I. Merkle, P. Hofmann, A. Stelzner, D. Gemsa, Cytokine
proﬁles in heart, spleen, and thymus during the acute stage of experimental
coxsackievirus B3-induced chronicmyocarditis, J. Med. Virol. 61 (2000) 518–526.
[150] T. Shioi, A. Matsumori, S. Sasayama, Persistent expression of cytokine in the
chronic stage of viral myocarditis in mice, Circulation 94 (1996) 2930–2937.
[151] M. Satoh, G. Tamura, I. Segawa, A. Tashiro, K. Hiramori, R. Satodate, Expression of
cytokine genes and presence of enteroviral genomic RNA in endomyocardial
biopsy tissues of myocarditis and dilated cardiomyopathy, Virchows Arch. 427
(1996) 503–509.
[152] Y. Sakata, A.L. Chancey, V.G. Divakaran, K. Sekiguchi, N. Sivasubramanian, D.L.
Mann, Transforming growth factor-beta receptor antagonism attenuates myo-
cardial ﬁbrosis in mice with cardiac-restricted overexpression of tumor necrosis
factor, Basic Res. Cardiol. 103 (2008) 60–68.
[153] C.H. Heldin, U. Eriksson, A. Ostman, Newmembers of the platelet-derived growth
factor family of mitogens, Arch. Biochem. Biophys. 398 (2002) 284–290.
[154] K. Grun, B. Markova, F.D. Bohmer, A. Berndt, H. Kosmehl, C. Leipner, Elevated
expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis, Eur.
Heart J. 26 (2005) 728–739.
[155] R. Wessely, K. Klingel, K.U. Knowlton, R. Kandolf, Cardioselective infection with
coxsackievirus B3 requires intact type I interferon signaling: implications for
mortality and early viral replication, Circulation 103 (2001) 756–761.
[156] C. Leipner, K. Grun, A. Muller, E. Buchdunger, L. Borsi, H. Kosmehl, A. Berndt, T.
Janik, A. Uecker, M. Kiehntopf, F.D. Bohmer, Imatinib mesylate attenuates ﬁbrosis
in coxsackievirus b3-induced chronic myocarditis, Cardiovasc. Res. 79 (2008)
118–126.
[157] M. Neef, M. Ledermann, H. Saegesser, V. Schneider, N. Widmer, L.A. Decosterd,
B. Rochat, J. Reichen, Oral imatinib treatment reduces early ﬁbrogenesis but
does not prevent progression in the long term, J. Hepatol. 44 (2006) 167–175.
[158] R.T. Paniagua, O. Sharpe, P.P. Ho, S.M. Chan, A. Chang, J.P. Higgins, B.H. Tomooka,
F.M. Thomas, J.J. Song, S.B. Goodman, D.M. Lee, M.C. Genovese, P.J. Utz, L. Steinman,
W.H. Robinson, Selective tyrosine kinase inhibition by imatinib mesylate for the
treatment of autoimmune arthritis, J. Clin. Invest. 116 (2006) 2633–2642.
[159] S. Wang, M.C. Wilkes, E.B. Leof, R. Hirschberg, Imatinib mesylate blocks a non-
Smad TGF-beta pathway and reduces renal ﬁbrogenesis in vivo, FASEB J. 19
(2005) 1–11.
[160] Y. Aono, Y. Nishioka, M. Inayama, M. Ugai, J. Kishi, H. Uehara, K. Izumi, S. Sone,
Imatinib as a novel antiﬁbrotic agent in bleomycin-induced pulmonary ﬁbrosis in
mice, Am. J. Respir. Crit. Care Med. 171 (2005) 1279–1285.
[161] M.C.Wilkes, H.Mitchell, S.G. Penheiter, J.J. Dore, K. Suzuki, M. Edens, D.K. Sharma,
R.E. Pagano, E.B. Leof, Transforming growth factor-beta activation of phosphati-
dylinositol 3-kinase is independent of Smad2 and Smad3 and regulates ﬁbroblast
responses via p21-activated kinase-2, Cancer Res. 65 (2005) 10431–10440.[162] C.E. Daniels, M.C.Wilkes, M. Edens, T.J. Kottom, S.J. Murphy, A.H. Limper, E.B. Leof,
Imatinib mesylate inhibits the proﬁbrogenic activity of TGF-beta and prevents
bleomycin-mediated lung ﬁbrosis, J. Clin. Invest. 114 (2004) 1308–1316.
[163] R. Plattner, L. Kadlec, K.A. DeMali, A. Kazlauskas, A.M. Pendergast, c-Abl is
activated by growth factors and Src family kinases and has a role in the cellular
response to PDGF, Genes Dev. 13 (1999) 2400–2411.
[164] U. Seeland, C. Haeuseler, R. Hinrichs, S. Rosenkranz, T. Pﬁtzner, K. Scharffetter-
Kochanek, M. Bohm, Myocardial ﬁbrosis in transforming growth factor-beta(1)
(TGF-beta(1)) transgenic mice is associated with inhibition of interstitial
collagenase, Eur. J. Clin. Invest. 32 (2002) 295–303.
[165] H. Xiao, Y.Y. Zhang, Understanding the role of transforming growth factor-beta
signalling in the heart: overview of studies using genetic mouse models, Clin.
Exp. Pharmacol. Physiol. 35 (2008) 335–341.
[166] K.J. Gordon, G.C. Blobe, Role of transforming growth factor-beta superfamily
signaling pathways in human disease, Biochim. Biophys. Acta 1782 (2008)
197–228.
[167] A.L. Mead, T.T. Wong, M.F. Cordeiro, I.K. Anderson, P.T. Khaw, Evaluation of anti-
TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma
surgery, Invest. Ophthalmol. Vis. Sci. 44 (2003) 3394–3401.
[168] C.P. Denton, P.A. Merkel, D.E. Furst, D. Khanna, P. Emery, M. Hsu, N. Silliman, J.
Streisand, J. Powell, A. Akesson, J. Coppock, F. Hoogen, A. Herrick, M.D. Mayes, D.
Veale, J. Haas, S. Ledbetter, J.H. Korn, C.M. Black, J.R. Seibold, Recombinant human
anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a
multicenter, randomized, placebo-controlled phase I/II trial of CAT-192, Arthritis
Rheum. 56 (2007) 323–333.
[169] [http://clinicaltrials.gov/ct2/show/NCT00125385].
[170] [http://clinicaltrials.gov/ct2/show/NCT00464321].
[171] [http://clinicaltrials.gov/ct2/show/NCT00356460].
[172] P. Juarez, M.M. Vilchis-Landeros, J. Ponce-Coria, V. Mendoza, R. Hernandez-
Pando, N.A. Bobadilla, F. Lopez-Casillas, Soluble betaglycan reduces renal
damage progression in db/db mice, Am. J. Physiol. Renal. Physiol. 292 (2007)
F321–F329.
[173] M.A. Rowland-Goldsmith, H. Maruyama, K. Matsuda, T. Idezawa, M. Ralli, S. Ralli,
M. Korc, Soluble type II transforming growth factor-beta receptor attenuates
expression of metastasis-associated genes and suppresses pancreatic cancer cell
metastasis, Mol. Cancer Ther. 1 (2002) 161–167.
[174] R.S. Muraoka, N. Dumont, C.A. Ritter, T.C. Dugger, D.M. Brantley, J. Chen, E.
Easterly, L.R. Roebuck, S. Ryan, P.J. Gotwals, V. Koteliansky, C.L. Arteaga, Blockade
of TGF-beta inhibits mammary tumor cell viability, migration, and metastases,
J. Clin. Invest. 109 (2002) 1551–1559.
[175] P. Hau, P. Jachimczak, R. Schlingensiepen, F. Schulmeyer, T. Jauch, A.
Steinbrecher, A. Brawanski, M. Proescholdt, J. Schlaier, J. Buchroithner, J. Pichler,
G. Wurm, M. Mehdorn, R. Strege, G. Schuierer, V. Villarrubia, F. Fellner, O. Jansen,
T. Straube, V. Nohria, M. Goldbrunner, M. Kunst, S. Schmaus, G. Stauder, U.
Bogdahn, K.H. Schlingensiepen, Inhibition of TGF-beta2withAP12009 in recurrent
malignant gliomas: from preclinical to phase I/II studies, Oligonucleotides 17
(2007) 201–212.
[176] J. Nemunaitis, R.O. Dillman, P.O. Schwarzenberger, N. Senzer, C. Cunningham,
J. Cutler, A. Tong, P. Kumar, B. Pappen, C. Hamilton, E. DeVol, P.B. Maples, L.
Liu, T. Chamberlin, D.L. Shawler, H. Fakhrai, Phase II study of belagenpuma-
tucel-L, a transforming growth factor beta-2 antisense gene-modiﬁed
allogeneic tumor cell vaccine in non-small-cell lung cancer, J. Clin. Oncol.
24 (2006) 4721–4730.
[177] E. Suzuki, S. Kim, H.K. Cheung, M.J. Corbley, X. Zhang, L. Sun, F. Shan, J. Singh, W.C.
Lee, S.M. Albelda, L.E. Ling, A novel small-molecule inhibitor of transforming
growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma
tumor growth in vivo and prevents tumor recurrence after surgical resection,
Cancer Res. 67 (2007) 2351–2359.
[178] N.G. Frangogiannis, G. Ren, O. Dewald, P. Zymek, S. Haudek, A. Koerting, K.
Winkelmann, L.H. Michael, J. Lawler, M.L. Entman, Critical role of endogenous
thrombospondin-1 in preventing expansion of healing myocardial infarcts,
Circulation 111 (2005) 2935–2942.
[179] S.M. Chuva de Sousa Lopes, A. Feijen, J. Korving, O. Korchynskyi, J. Larsson, S.
Karlsson, P. ten Dijke, K.M. Lyons, R. Goldschmeding, P. Doevendans, C.L.
Mummery, Connective tissue growth factor expression and Smad signaling
during mouse heart development and myocardial infarction, Dev. Dyn. 231
(2004) 542–550.
[180] I. Gotis-Graham, P.J. Hogg, H.P. McNeil, Signiﬁcant correlation between
thrombospondin 1 and serine proteinase expression in rheumatoid synovium,
Arthritis Rheum. 40 (1997) 1780–1787.
[181] F. Wu, T. Dassopoulos, L. Cope, A. Maitra, S.R. Brant, M.L. Harris, T.M. Bayless,
G. Parmigiani, S. Chakravarti, Genome-wide gene expression differences in
Crohn's disease and ulcerative colitis from endoscopic pinch biopsies:
insights into distinctive pathogenesis, Inﬂamm. Bowel Dis. 13 (2007)
807–821.
[182] N.A. Wahab, L. Schaefer, B.S. Weston, O. Yiannikouris, A. Wright, A. Babelova, R.
Schaefer, R.M. Mason, Glomerular expression of thrombospondin-1, transforming
growth factor beta and connective tissue growth factor at different stages of
diabetic nephropathy and their interdependent roles in mesangial response to
diabetic stimuli, Diabetologia 48 (2005) 2650–2660.
[183] F.M. Brennan, D. Chantry, M. Turner, B. Foxwell, R. Maini, M. Feldmann, Detection
of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack
of effect on spontaneous cytokine production in joint cell cultures, Clin. Exp.
Immunol. 81 (1990) 278–285.
[184] J. Hao, H. Ju, S. Zhao, A. Junaid, T. Scammell-La Fleur, I.M. Dixon,
Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in
756 D. Pohlers et al. / Biochimica et Biophysica Acta 1792 (2009) 746–756the chronic phase of myocardial infarct scar healing, J. Mol. Cell Cardiol.
31 (1999) 667–678.
[185] J. Waltenberger, L. Lundin, K. Oberg, E. Wilander, K. Miyazono, C.H. Heldin,
K. Funa, Involvement of transforming growth factor-beta in the formation
of ﬁbrotic lesions in carcinoid heart disease, Am. J. Pathol 142 (1993)
71–78.[186] S. Klahr, Mechanisms of progression of chronic renal damage, J. Nephrol. 12
(Suppl. 2) (1999) S53–S62.
[187] S. Schultze-Mosgau, F. Wehrhan, K. Amann, M. Radespiel-Troger, F. Rodel, G.G.
Grabenbauer, In vivo TGF-beta 3 expression during wound healing in
irradiated tissue. An experimental study, Strahlenther. Onkol. 179 (2003)
410–416.
